Penlac and Pantoprazole drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Penlac (ciclopirox) and Pantoprazole (pantoprazole sodium). Common drug interactions include chronic kidney disease among females and renal failure among males.

The phase IV clinical study analyzes what interactions people have when they take Penlac and Pantoprazole. It is created by eHealthMe based on reports of 18 people who take the same drugs from the FDA, and is updated regularly.

What is Penlac?

Penlac has active ingredients of ciclopirox. eHealthMe is studying from 492 Penlac users. Check the latest studies of Penlac.

What is Pantoprazole?

Pantoprazole has active ingredients of pantoprazole sodium. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 285,165 Pantoprazole users. Check the latest studies of Pantoprazole.



On Jul, 20, 2026

18 people who take Penlac and Pantoprazole together, and have interactions are studied.

Penlac and Pantoprazole drug interactions.

What are the common drug interactions of Penlac and Pantoprazole, by gender? *:

female:

  1. Chronic kidney disease
  2. Clavicle fracture
  3. Nephropathy (damage to or disease of a kidney)
  4. Renal failure (kidney dysfunction)
  5. Syncope (loss of consciousness with an inability to maintain postural tone)
  6. Anaemia (lack of blood)
  7. Asthenia (weakness)
  8. Azotaemia (excess of urea or other nitrogenous compounds in the blood)
  9. Confusional state
  10. Dehydration (dryness resulting from the removal of water)

male:

  1. Renal failure (kidney dysfunction)
  2. Anxiety
  3. Dizziness
  4. Dyspepsia (indigestion)
  5. Fluid overload (too much fluid in the blood)
  6. Haematocrit decreased
  7. Loss of consciousness
  8. Malignant hypertension (a hypertensive emergency is a condition in which elevated blood pressure results in target organ damage)
  9. Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
  10. Nausea (feeling of having an urge to vomit)

What are the common drug interactions of Penlac and Pantoprazole, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Pancreatitis (inflammation of pancreas)

50-59:

  1. Asthenia (weakness)
  2. Azotaemia (excess of urea or other nitrogenous compounds in the blood)
  3. Confusional state
  4. Dehydration (dryness resulting from the removal of water)
  5. Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
  6. Nephropathy toxic (damage to kidney due to toxins)
  7. Somnolence (a state of near-sleep, a strong desire for sleep)
  8. Anaemia (lack of blood)
  9. Blood lactic acid increased
  10. Blood thyroid stimulating hormone decreased

60+:

  1. Renal failure (kidney dysfunction)
  2. Anxiety
  3. Dizziness
  4. Dyspepsia (indigestion)
  5. Fluid overload (too much fluid in the blood)
  6. Haematocrit decreased
  7. Loss of consciousness
  8. Malignant hypertension (a hypertensive emergency is a condition in which elevated blood pressure results in target organ damage)
  9. Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
  10. Nausea (feeling of having an urge to vomit)

What are the existing conditions these people have? *

  1. Erdheim-Chester Disease (abnormal multiplication of a specific type of white blood cells): 6 people, 33.33%
  2. High Blood Pressure: 4 people, 22.22%
  3. Diabetes: 3 people, 16.67%
  4. High Blood Cholesterol: 3 people, 16.67%
  5. Cardiac Disorder: 2 people, 11.11%
  6. Neuropathy Peripheral (surface nerve damage): 2 people, 11.11%
  7. Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 2 people, 11.11%
  8. Gout (uric acid crystals building up in the body): 2 people, 11.11%
  9. General Physical Health Deterioration (weak health status): 1 person, 5.56%
  10. Coronary Heart Disease (narrowing or blockage of the coronary arteries): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Penlac and Pantoprazole?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Penlac and Pantoprazole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Penlac:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Pantoprazole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Penlac and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pantoprazole and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ciclopirox and pantoprazole sodium (the active ingredients of Penlac and Pantoprazole, respectively), and Penlac and Pantoprazole (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: